Evidence Snapshot
What this grade covers
Mature HUMAN Galanin. At least two controlled human studies administered synthetic human Galanin directly. Older studies administering porcine Galanin are comparator evidence only because human and porcine Galanin differ in sequence.
Regulatory Context
Galanin is an investigational endogenous human peptide. No FDA-approved Galanin therapeutic product or subject-specific regulatory action has been identified in the current source set.
Research Takeaway
Human Galanin is a mature neuropeptide derived from the GAL precursor and is distinct from the separate mature peptide GMAP and from Galanin-like peptide (GALP).
Evidence boundary: Shared precursor regions or receptor-family biology do not permit evidence transfer from GMAP, GALP, or Alarin.
See all 6 evidence claims →Quick Summary
Galanin is a mature human neuropeptide produced from the GAL precursor, distinct from the co-produced peptide GMAP as well as from Galanin-Like Peptide (GALP) and Alarin, both encoded by separate genes. At least two controlled human studies have administered synthetic human Galanin directly, producing measurable acute endocrine effects - most notably a marked growth-hormone response. Older studies that administered porcine Galanin, which differs in sequence from the human peptide, are retained only as comparator evidence. Human Galanin's direct-administration evidence remains limited to small, acute physiology studies and does not establish therapeutic efficacy.
Mechanism & Research Overview
In a six-person hyperglycemic-clamp study, synthetic human Galanin infusion produced a marked growth-hormone response while not materially changing insulin/C-peptide responses or glucose handling under the study conditions, with rapid plasma disappearance. A separate randomized-order human study found Galanin modified anterior-pituitary hormone responses in an acute endocrine challenge model. Earlier studies using porcine Galanin, a non-identical sequence, are treated as species-comparator context rather than exact-human-Galanin evidence.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Human Galanin is a mature neuropeptide derived from the GAL precursor and is distinct from the separate mature peptide GMAP and from Galanin-like peptide (GALP).
Does not establish
Evidence boundary: Shared precursor regions or receptor-family biology do not permit evidence transfer from GMAP, GALP, or Alarin.
Sources: GAL galanin and GMAP prepropeptide [Homo sapiens]
Supported
Synthetic human Galanin has been administered intravenously in small controlled studies of healthy volunteers and produces measurable human endocrine pharmacology.
Does not establish
Evidence boundary: These studies demonstrate acute human pharmacology, not established therapeutic efficacy.
Sources: On the effects of human galanin in man; Physiological role of galanin in the regulation of anterior pituitary function in humans
Supported
In a six-person hyperglycemic-clamp study, human Galanin strongly stimulated growth-hormone secretion while showing little effect on pancreatic endocrine secretion or glucose handling under those experimental conditions.
Does not establish
Evidence boundary: Single small acute physiology study; no treatment-benefit inference.
Supported
A randomized-order volunteer experiment found that human Galanin modified anterior-pituitary hormone responses in an acute endocrine challenge model.
Does not establish
Evidence boundary: Small experimental physiology study, not a clinical efficacy trial.
Sources: Physiological role of galanin in the regulation of anterior pituitary function in humans
Supported
Older human infusion studies using porcine Galanin are comparator evidence and should not be treated as exact-human-Galanin evidence.
Does not establish
Evidence boundary: The human Galanin paper explicitly notes important sequence differences from porcine Galanin.
Sources: On the effects of human galanin in man; Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man
Supported
The frozen direct-human-Galanin evidence is limited to very small acute administration studies and is insufficient to define a broad clinical safety profile.
Does not establish
Evidence boundary: Absence of major problems in small experimental studies is not evidence of long-term safety.
Sources: On the effects of human galanin in man; Physiological role of galanin in the regulation of anterior pituitary function in humans
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
In a small controlled study, human Galanin infusion produced a marked growth-hormone response.Safety Consideration
Human and porcine Galanin differ in sequence; porcine-Galanin study findings are comparator evidence only and do not establish exact-human-Galanin effects.Safety Consideration
Direct-human-Galanin evidence is limited to very small acute administration studies; long-term or repeated systemic safety is not established.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man ():
- Inhibitory effect of galanin on postprandial gastrointestinal motility and gut hormone release in humans ():
- On the effects of human galanin in man ():
- Physiological role of galanin in the regulation of anterior pituitary function in humans ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man | Six human volunteers in Galanin arm | Porcine Galanin did not show the anticipated pancreatic endocrine effect in this human experiment. | |||
| Inhibitory effect of galanin on postprandial gastrointestinal motility and gut hormone release in humans | Eight healthy volunteers | Galanin infusion altered GI motility and several postprandial hormone responses. | |||
| On the effects of human galanin in man | Six healthy volunteers under hyperglycemic clamp | Synthetic human Galanin infusion produced a marked GH response while not materially changing insulin/C-peptide responses or glucose handling under the study conditions; plasma disappearance was rapid. | |||
| Physiological role of galanin in the regulation of anterior pituitary function in humans | Six healthy men, randomized order challenge | Human Galanin modified anterior-pituitary hormone responses in an acute controlled volunteer protocol. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| GAL galanin and GMAP prepropeptide [Homo sapiens] | Homo sapiens identity record | The human GAL gene encodes a precursor proteolytically processed into distinct mature Galanin and GMAP peptides. | No source link available |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-24.
Follow research updates for Galanin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.